Compare INTG & CELU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | INTG | CELU |
|---|---|---|
| Founded | 1965 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Building operators | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 38.9M | 34.5M |
| IPO Year | N/A | N/A |
| Metric | INTG | CELU |
|---|---|---|
| Price | $27.85 | $1.30 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $6.00 |
| AVG Volume (30 Days) | 17.1K | ★ 81.0K |
| Earning Date | 02-13-2026 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $65,385,000.00 | $40,578,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $76.00 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 9.82 | N/A |
| 52 Week Low | $9.57 | $1.00 |
| 52 Week High | $42.50 | $4.35 |
| Indicator | INTG | CELU |
|---|---|---|
| Relative Strength Index (RSI) | 51.23 | 40.30 |
| Support Level | $25.00 | $1.20 |
| Resistance Level | $28.40 | $1.31 |
| Average True Range (ATR) | 1.92 | 0.12 |
| MACD | 0.32 | 0.02 |
| Stochastic Oscillator | 73.99 | 56.06 |
The Intergroup Corp is an us-based company operating in the real estate sector. It is formed to buy, develop, operate, rehabilitate and dispose of real property of various types and descriptions, and to engage in other related business and investment activities. The company operates through three segments namely Hotel Operations, Real Estate Operations, and Investment Transactions. The Hotel Operations segment which generates the majority of the revenue covers the operation of the Hilton hotel and garage. The Real Estate Operations segment consists of the operation of multifamily rental properties whereas the Investment Transactions segment includes an investment of cash in marketable securities and other investments.
Celularity Inc is a clinical-stage biotechnology company developing off-the-shelf placental-derived allogeneic cell therapies including genetically modified and unmodified NK cells, engineered T cells including CAR-T cells, and mesenchymal-like adherent stromal cells, targeting indications across cancer, immunologic, infectious, and degenerative diseases. It manages its operations through an evaluation of three distinct business segments which include Cell Therapy, Degenerative Disease, and bio-banking. The company generates the majority of its revenue from the bio-banking segment.